LivingGLP1
parallel randomized trial

S003078

Design

Randomized
60
Start year
2015
Treatment
8 weeks, follow-up 8 weeks
Countries
China (1 sites)
Sponsor
Science and Technology Benefit Fund of Xiamen Technology Bureau (non industry)
Eligibility
newly diagnosed T2D; age 18 to 40; BMI 25 to 35; HbA1c 6.5 to 9 percent

Conduct and analysis

Blinding
open label
Sequence generation
not reported
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
Missing data

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1Liraglutide 1.2 mg subcutaneous once daily
Liraglutide
lifestyle: standard30
A2Metformin
Metformin
lifestyle: standard30

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticLiraglutide 1.2 mg subcutaneous once daily
A1
Metformin
A2
agemean (years)32.6735.27
agesd (years)5.465.85
bmimean (kg/m2)28.6326.16
bmisd (kg/m2)3.863.1
femalen1010
hba1cmean (percent)8.497.77
hba1csd (percent)1.811.44
sbpmean (mmHg)122120
sbpsd (mmHg)1611
waistmean (cm)92.2088.27
waistsd (cm)11.998.22
weightmean (kg)8172
weightsd (kg)1711

Results

3 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
HbA1c change (2 lines; O01)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
8A1final6.92 percent0.81not stated; other; R0025354:Results
8A2final6.43 percent0.71not stated; other; R0025354:Results
Body weight change in kilograms (diabetes) (1 lines; O02)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
8A1final78 kg16not stated; other; R0025354:Results